

cancers



an Open Access Journal by MDPI

Small Cell Lung Cancer: A New Era Is Beginning?

Guest Editors:

Prof. Dr. Alessandro Morabito

Thoracic Medical Oncology,
Istituto Nazionale Tumori IRCCS
Fondazione Pascale—IRCCS di
Napoli, 80131 Naples, Italy

Prof. Dr. Christian Rolfo

Professor of Medicine, Director of
Thoracic Medical Oncology
Program, Director of Early
Clinical Trials, Experimental
Therapeutics Research Program,
Marlene and Stewart
Greenebaum Comprehensive
Cancer Center, University of
Maryland School of Medicine,
Baltimore, MD, USA

Deadline for manuscript
submissions:

closed (31 December 2020)

Message from the Guest Editors

Dear Colleagues,

Small-cell lung cancer (SCLC) is the most aggressive lung cancer: No significant progress has been made in decades, and platinum-based chemotherapy has for a long time represented the standard of care. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly [ADP-ribose] polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody–drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approaches for limited disease. This Special Issue will highlight the current state of treatment of limited and extensive SCLC, focusing on biology of SCLC, immune-checkpoint inhibitors, antibody–drug conjugates, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques.

Prof. Dr. Alessandro Morabito


Prof. Dr. Christian Rolfo

Guest Editors



mdpi.com/si/50230

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI